Lycus Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 M
- Revenue Growth 26.77%
- Profit Growth -14.02%
- Ebitda -2611.72%
- Net Worth 12.89%
- Total Assets 25.88%
About Lycus Pharma
Lycus Pharma Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 July 2009 and has a history of 15 years and six months. Its registered office is in Pathanamthitta, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 M.
Company Details
-
Location
Pathanamthitta, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52311KL2009PTC024412
-
Company No.
024412
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jul 2009
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Lycus Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lathish Nair
|
Managing Director | 30-Mar-2012 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Jose Joseph
|
Director | 06-Jul-2009 | Current |
|
Jayan Padmanabhan
|
Director | 30-Mar-2012 | Current |
|
Jacob Job
|
Director | 30-Mar-2012 | Current |
Financial Performance of Lycus Pharma.
Lycus Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 26.77% increase. The company also saw a substantial fall in profitability, with a 14.02% decrease in profit. The company's net worth Soared by an impressive increase of 12.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lycus Pharma?
In 2019, Lycus Pharma had a promoter holding of 18.90% and a public holding of 81.10%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Feb 2015 | Others | ₹1.50 M | Open |
How Many Employees Work at Lycus Pharma?
Unlock and access historical data on people associated with Lycus Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lycus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lycus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
